XERIS BIOPHARMA HOLDINGS INC's ticker is and the CUSIP is 98422E103. A total of 100 filers reported holding XERIS BIOPHARMA HOLDINGS INC in Q4 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $126,631 | -16.5% | 68,081 | +17.6% | 0.00% | – |
Q2 2023 | $151,640 | +4.7% | 57,878 | -34.9% | 0.00% | – |
Q1 2023 | $144,833 | +85.8% | 88,855 | +51.6% | 0.00% | – |
Q4 2022 | $77,970 | -13.4% | 58,624 | +1.5% | 0.00% | – |
Q3 2022 | $90,000 | -11.8% | 57,741 | -13.3% | 0.00% | – |
Q2 2022 | $102,000 | – | 66,580 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CAXTON CORP | 5,641,920 | $10,493,971 | 39.87% |
Stonepine Capital Management, LLC | 5,915,372 | $11,002,592 | 3.66% |
MPM BioImpact LLC | 3,987,967 | $7,417,619 | 1.98% |
SINECERA CAPITAL, LLC | 253,101 | $470,768 | 0.63% |
Opaleye Management Inc. | 390,000 | $725,400 | 0.24% |
Alpine Global Management, LLC | 300,000 | $558,000 | 0.14% |
DELTEC ASSET MANAGEMENT LLC | 315,246 | $586,358 | 0.13% |
Redmile Group, LLC | 1,046,587 | $1,946,652 | 0.09% |
GSA CAPITAL PARTNERS LLP | 381,231 | $709 | 0.06% |
Soleus Capital Management, L.P. | 304,083 | $565,594 | 0.05% |